Company profile VTYX
After 39 days of this quarter the interest is at 52.0. Based on that we can calculate that during remaining 52 days it will total up to 121.0. Ventyx Biosciences expected interest is significantly lower compared to previous quarter (-59.0%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 37 | 19 -48.6% QoQ | 92 384.2% QoQ | 146 58.7% QoQ |
| 2020 | 91 145.9% YoY -37.7% QoQ | 80 321.1% YoY -12.1% QoQ | 16 -82.6% YoY -80.0% QoQ | 124 -15.1% YoY 675.0% QoQ |
| 2021 | 78 -14.3% YoY -37.1% QoQ | 113 41.2% YoY 44.9% QoQ | 64 300.0% YoY -43.4% QoQ | 84 -32.3% YoY 31.2% QoQ |
| 2022 | 109 39.7% YoY 29.8% QoQ | 66 -41.6% YoY -39.4% QoQ | 194 203.1% YoY 193.9% QoQ | 169 101.2% YoY -12.9% QoQ |
| 2023 | 189 73.4% YoY 11.8% QoQ | 223 237.9% YoY 18.0% QoQ | 192 -1.0% YoY -13.9% QoQ | 295 74.6% YoY 53.6% QoQ |
| 2024 | 52 -72.5% YoY -82.4% QoQ | - | - | - |
The average 5 years interest of Ventyx Biosciences was 9.32 per week. The last year interest of Ventyx Biosciences compared to the last 5 years has changed by 84.66%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 155.72%.
There is not enough data for VTX958 to provide analysis
There is not enough data for VTX958 to provide correlation calculation
There is not enough data for VTX958 to provide analysis
There is not enough data for allosteric tyrosine kinase type 2 inhibitor to provide analysis
There is not enough data for allosteric tyrosine kinase type 2 inhibitor to provide correlation calculation
There is not enough data for allosteric tyrosine kinase type 2 inhibitor to provide analysis
After 39 days of this quarter the interest is at 439.0. Based on that we can calculate that during remaining 52 days it will total up to 1024.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 488 | 736 50.8% QoQ | 748 1.6% QoQ | 827 10.6% QoQ |
| 2020 | 754 54.5% YoY -8.8% QoQ | 813 10.5% YoY 7.8% QoQ | 759 1.5% YoY -6.6% QoQ | 924 11.7% YoY 21.7% QoQ |
| 2021 | 1005 33.3% YoY 8.8% QoQ | 1049 29.0% YoY 4.4% QoQ | 1003 32.1% YoY -4.4% QoQ | 969 4.9% YoY -3.4% QoQ |
| 2022 | 1115 10.9% YoY 15.1% QoQ | 1027 -2.1% YoY -7.9% QoQ | 1050 4.7% YoY 2.2% QoQ | 1031 6.4% YoY -1.8% QoQ |
| 2023 | 1134 1.7% YoY 10.0% QoQ | 1085 5.6% YoY -4.3% QoQ | 1031 -1.8% YoY -5.0% QoQ | 1222 18.5% YoY 18.5% QoQ |
| 2024 | 439 -61.3% YoY -64.1% QoQ | - | - | - |
The average 5 years interest of psoriasis treatment was 73.6 per week. The last year interest of psoriasis treatment compared to the last 5 years has changed by 14.61%. The interest for psoriasis treatment is relatively stable in the last 5 years. The last year interest is quite higher compared to 5 years ago. It has increased by 40.49%.
After 39 days of this quarter the interest is at 327.0. Based on that we can calculate that during remaining 52 days it will total up to 763.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 441 | 751 70.3% QoQ | 618 -17.7% QoQ | 678 9.7% QoQ |
| 2020 | 706 60.1% YoY 4.1% QoQ | 675 -10.1% YoY -4.4% QoQ | 737 19.3% YoY 9.2% QoQ | 818 20.6% YoY 11.0% QoQ |
| 2021 | 820 16.1% YoY 0.2% QoQ | 907 34.4% YoY 10.6% QoQ | 668 -9.4% YoY -26.4% QoQ | 637 -22.1% YoY -4.6% QoQ |
| 2022 | 799 -2.6% YoY 25.4% QoQ | 696 -23.3% YoY -12.9% QoQ | 774 15.9% YoY 11.2% QoQ | 680 6.8% YoY -12.1% QoQ |
| 2023 | 865 8.3% YoY 27.2% QoQ | 735 5.6% YoY -15.0% QoQ | 778 0.5% YoY 5.9% QoQ | 787 15.7% YoY 1.2% QoQ |
| 2024 | 327 -62.2% YoY -58.4% QoQ | - | - | - |
The average 5 years interest of psoriatic arthritis treatment was 57.08 per week. The last year interest of psoriatic arthritis treatment compared to the last 5 years has changed by 4.03%. The interest for psoriatic arthritis treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 10.43%.
After 39 days of this quarter the interest is at 182.0. Based on that we can calculate that during remaining 52 days it will total up to 425.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 339 | 566 67.0% QoQ | 438 -22.6% QoQ | 347 -20.8% QoQ |
| 2020 | 430 26.8% YoY 23.9% QoQ | 458 -19.1% YoY 6.5% QoQ | 339 -22.6% YoY -26.0% QoQ | 278 -19.9% YoY -18.0% QoQ |
| 2021 | 433 0.7% YoY 55.8% QoQ | 389 -15.1% YoY -10.2% QoQ | 398 17.4% YoY 2.3% QoQ | 337 21.2% YoY -15.3% QoQ |
| 2022 | 394 -9.0% YoY 16.9% QoQ | 319 -18.0% YoY -19.0% QoQ | 405 1.8% YoY 27.0% QoQ | 517 53.4% YoY 27.7% QoQ |
| 2023 | 611 55.1% YoY 18.2% QoQ | 340 6.6% YoY -44.4% QoQ | 384 -5.2% YoY 12.9% QoQ | 446 -13.7% YoY 16.1% QoQ |
| 2024 | 182 -70.2% YoY -59.2% QoQ | - | - | - |
The average 5 years interest of Crohn's disease treatment was 31.99 per week. The last year interest of Crohn's disease treatment compared to the last 5 years has changed by -2.13%. The interest for Crohn's disease treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -13.44%.
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. VTX002 expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 0 | 121 inf% QoQ | 24 -80.2% QoQ |
| 2020 | 180 inf% YoY 650.0% QoQ | 48 inf% YoY -73.3% QoQ | 24 -80.2% YoY -50.0% QoQ | 141 487.5% YoY 487.5% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 84 75.0% YoY inf% QoQ | 101 320.8% YoY 20.2% QoQ | 85 -39.7% YoY -15.8% QoQ |
| 2022 | 126 inf% YoY 48.2% QoQ | 113 34.5% YoY -10.3% QoQ | 92 -8.9% YoY -18.6% QoQ | 72 -15.3% YoY -21.7% QoQ |
| 2023 | 132 4.8% YoY 83.3% QoQ | 66 -41.6% YoY -50.0% QoQ | 116 26.1% YoY 75.8% QoQ | 91 26.4% YoY -21.6% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of VTX002 was 6.19 per week. The last year interest of VTX002 compared to the last 5 years has changed by 10.02%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 8.96%.
There is not enough data for sphingosine 1 phosphate receptor modulator to provide analysis
There is not enough data for sphingosine 1 phosphate receptor modulator to provide correlation calculation
There is not enough data for sphingosine 1 phosphate receptor modulator to provide analysis
After 39 days of this quarter the interest is at 282.0. Based on that we can calculate that during remaining 52 days it will total up to 658.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 472 | 786 66.5% QoQ | 648 -17.6% QoQ | 699 7.9% QoQ |
| 2020 | 716 51.7% YoY 2.4% QoQ | 632 -19.6% YoY -11.7% QoQ | 738 13.9% YoY 16.8% QoQ | 803 14.9% YoY 8.8% QoQ |
| 2021 | 739 3.2% YoY -8.0% QoQ | 850 34.5% YoY 15.0% QoQ | 877 18.8% YoY 3.2% QoQ | 740 -7.8% YoY -15.6% QoQ |
| 2022 | 888 20.2% YoY 20.0% QoQ | 826 -2.8% YoY -7.0% QoQ | 859 -2.1% YoY 4.0% QoQ | 874 18.1% YoY 1.7% QoQ |
| 2023 | 862 -2.9% YoY -1.4% QoQ | 828 0.2% YoY -3.9% QoQ | 895 4.2% YoY 8.1% QoQ | 871 -0.3% YoY -2.7% QoQ |
| 2024 | 282 -67.3% YoY -67.6% QoQ | - | - | - |
The average 5 years interest of ulcerative colitis treatment was 60.86 per week. The last year interest of ulcerative colitis treatment compared to the last 5 years has changed by 6.59%. The interest for ulcerative colitis treatment is relatively stable in the last 5 years. The last year interest is quite higher compared to 5 years ago. It has increased by 15.72%.
There is not enough data for VTX2735 to provide analysis
There is not enough data for VTX2735 to provide correlation calculation
There is not enough data for VTX2735 to provide analysis
There is not enough data for NOD-like receptor protein 3 inflammasome inhibitor to provide analysis
There is not enough data for NOD-like receptor protein 3 inflammasome inhibitor to provide correlation calculation
There is not enough data for NOD-like receptor protein 3 inflammasome inhibitor to provide analysis
There is not enough data for cryopyrin-associated periodic syndrome treatment to provide analysis
There is not enough data for cryopyrin-associated periodic syndrome treatment to provide correlation calculation
There is not enough data for cryopyrin-associated periodic syndrome treatment to provide analysis
There is not enough data for VTX3232 to provide analysis
There is not enough data for VTX3232 to provide correlation calculation
There is not enough data for VTX3232 to provide analysis
After 39 days of this quarter the interest is at 17.0. Based on that we can calculate that during remaining 52 days it will total up to 40.0. NLRP3 inhibitor expected interest is significantly lower compared to previous quarter (-40.3%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 94 | 97 3.2% QoQ | 38 -60.8% QoQ | 36 -5.3% QoQ |
| 2020 | 26 -72.3% YoY -27.8% QoQ | 34 -64.9% YoY 30.8% QoQ | 137 260.5% YoY 302.9% QoQ | 24 -33.3% YoY -82.5% QoQ |
| 2021 | 260 900.0% YoY 983.3% QoQ | 52 52.9% YoY -80.0% QoQ | 137 0.0% YoY 163.5% QoQ | 79 229.2% YoY -42.3% QoQ |
| 2022 | 52 -80.0% YoY -34.2% QoQ | 84 61.5% YoY 61.5% QoQ | 141 2.9% YoY 67.9% QoQ | 103 30.4% YoY -27.0% QoQ |
| 2023 | 57 9.6% YoY -44.7% QoQ | 163 94.0% YoY 186.0% QoQ | 93 -34.0% YoY -42.9% QoQ | 67 -35.0% YoY -28.0% QoQ |
| 2024 | 17 -70.2% YoY -74.6% QoQ | - | - | - |
The average 5 years interest of NLRP3 inhibitor was 6.86 per week. The last year interest of NLRP3 inhibitor compared to the last 5 years has changed by 5.69%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 29.46%.
Google Trends for Ventyx Biosciences corporate governance
Not enough data for reliable calculations!
There is not enough data for Ventyx Biosciences corporate governance to provide analysis
There is not enough data for Ventyx Biosciences corporate governance to provide correlation calculation
There is not enough data for Ventyx Biosciences corporate governance to provide analysis
There is not enough data for Ventyx Biosciences contact to provide analysis
There is not enough data for Ventyx Biosciences contact to provide correlation calculation
There is not enough data for Ventyx Biosciences contact to provide analysis
There is not enough data for Ventyx Biosciences careers. to provide analysis
There is not enough data for Ventyx Biosciences careers. to provide correlation calculation
There is not enough data for Ventyx Biosciences careers. to provide analysis